Lateral Flow Assay for Diagnosis of Histoplasmosis

侧流层析检测用于诊断组织胞浆菌病

基本信息

  • 批准号:
    8924705
  • 负责人:
  • 金额:
    $ 97.27万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2011
  • 资助国家:
    美国
  • 起止时间:
    2011-07-25 至 2017-03-31
  • 项目状态:
    已结题

项目摘要

 DESCRIPTION (provided by applicant): Progressive disseminated histoplasmosis is a common and serious opportunistic infection among individuals with HIV/AIDS. In many resource-limited areas, such as Latin America, incidence rates in HIV/AIDS can be >20%, with mortality rates among cases >30%. Successful treatment of histoplasmosis in patients with AIDS requires early diagnosis and treatment. As a consequence, there is a critical need for a rapid, effective and low-cost point-of-care (POC) diagnostic test for histoplasmosis. Currently, diagnosis of histoplasmosis relies on demonstration of the fungus in clinical specimens by histopathology or culture. Such methods have a low sensitivity, are time consuming, are expensive, and require trained personnel. An alternative approach to diagnosis is detection of shed fungal antigens in body fluids such as blood or urine. Immunoassays are a well-established means to diagnose fungal and microbial infections for a broad spectrum of infectious diseases. Importantly, immunoassays are readily adaptable to a POC format using platform technologies such as a lateral flow assay (LFA). In the Phase I STTR Grant #1 5R41AI096945-02 entitled "Point-of-care immunoassay for diagnosis of histoplasmosis in HIV/AIDS" a monoclonal antibody to a Histoplasma polysaccharide was developed and used to develop an LFA that accurately detects the presence of Histoplasma antigen in the urine of infected patients. The goal of this Phase II project is to further develop and validate the Histoplasma LFA for definitive diagnosis of histoplasmosis in the urine of HIV/AIDS infected patients in South America. Criteria for success of this Phase II SBIR proposal would be the generation of data to support a 510k application of a diagnostic assay that would definitively detect the presence of Histoplasma in the urine of infected patients, which could ultimately result in a dramatic decrease in the mortality associated with this disease.
 描述(由申请人提供):进行性播散性组织胞浆菌病是HIV/AIDS患者中常见的严重机会性感染。在许多资源有限的地区,如拉丁美洲,艾滋病毒/艾滋病的发病率可能超过20%,病例死亡率超过30%。艾滋病患者组织胞浆菌病的成功治疗需要早期诊断和治疗。因此,迫切需要一种快速、有效和低成本的组织胞浆菌病的床旁(POC)诊断测试。目前,组织胞浆菌病的诊断依赖于通过组织病理学或培养在临床标本中证实真菌。这种方法灵敏度低,耗时,昂贵,并且需要训练有素的人员。另一种诊断方法是检测体液如血液或尿液中的脱落真菌抗原。免疫测定是诊断广泛传染病的真菌和微生物感染的成熟方法。重要的是,使用平台技术如侧流测定(LFA),免疫测定容易适应于POC形式。在题为“用于诊断艾滋病毒/艾滋病组织胞浆菌病的护理点免疫测定”的第一阶段STTR资助#1 5 R41 AI 096945 -02中,开发了一种针对组织胞浆菌多糖的单克隆抗体,并用于开发准确检测组织胞浆菌抗原的LFA感染患者尿液中的存在。该II期项目的目标是进一步开发和验证组织胞浆菌LFA,用于南美洲HIV/AIDS感染患者尿液中组织胞浆菌病的明确诊断。该II期SBIR提案成功的标准是生成数据以支持诊断检测的510 k应用,该诊断检测将明确检测感染患者尿液中是否存在组织胞浆菌,这最终可能导致与该疾病相关的死亡率大幅降低。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Beverly Crider其他文献

Beverly Crider的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Beverly Crider', 18)}}的其他基金

Immunoassay for diagnosis of invasive fungal disease
用于诊断侵袭性真菌病的免疫分析
  • 批准号:
    8605511
  • 财政年份:
    2013
  • 资助金额:
    $ 97.27万
  • 项目类别:

相似海外基金

RESEARCH SUPPORT SERVICES FOR THE DIVISION OF ACQUIRED IMMUNODEFICIENCY SYNDROME
获得性免疫缺陷综合症分类的研究支持服务
  • 批准号:
    10219039
  • 财政年份:
    2020
  • 资助金额:
    $ 97.27万
  • 项目类别:
RESEARCH SUPPORT SERVICES FOR THE DIVISION OF ACQUIRED IMMUNODEFICIENCY SYNDROME
获得性免疫缺陷综合症分类的研究支持服务
  • 批准号:
    9981476
  • 财政年份:
    2019
  • 资助金额:
    $ 97.27万
  • 项目类别:
IGF::OT::IGF RESEARCH SUPPORT SERVICES FOR THE DIVISION OF ACQUIRED IMMUNODEFICIENCY SYNDROME
IGF::OT::IGF 针对获得性免疫缺陷综合症分类的研究支持服务
  • 批准号:
    9364184
  • 财政年份:
    2016
  • 资助金额:
    $ 97.27万
  • 项目类别:
Human Immunodeficiency Virus (HIV) and Acquired Immunodeficiency Syndrome (AIDS) in Saskatchewan- Where are we now and what does the future hold?
萨斯喀彻温省的人类免疫缺陷病毒(HIV)和获得性免疫缺陷综合症(艾滋病)——我们现在在哪里以及未来会怎样?
  • 批准号:
    236932
  • 财政年份:
    2011
  • 资助金额:
    $ 97.27万
  • 项目类别:
    Miscellaneous Programs
ACQUIRED IMMUNODEFICIENCY SYNDROME RESEARCH REVIEW COMMI
获得性免疫缺陷综合症研究审查委员会
  • 批准号:
    3554155
  • 财政年份:
    1991
  • 资助金额:
    $ 97.27万
  • 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME REVIEW
获得性免疫缺陷综合症审查
  • 批准号:
    6766860
  • 财政年份:
    1991
  • 资助金额:
    $ 97.27万
  • 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME RESEARCH REVIEW COMMI
获得性免疫缺陷综合症研究审查委员会
  • 批准号:
    3554156
  • 财政年份:
    1991
  • 资助金额:
    $ 97.27万
  • 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME REVIEW
获得性免疫缺陷综合症审查
  • 批准号:
    6256640
  • 财政年份:
    1991
  • 资助金额:
    $ 97.27万
  • 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME RESEARCH REVIEW
获得性免疫缺陷综合症研究综述
  • 批准号:
    2063342
  • 财政年份:
    1991
  • 资助金额:
    $ 97.27万
  • 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME REVIEW
获得性免疫缺陷综合症审查
  • 批准号:
    6091256
  • 财政年份:
    1991
  • 资助金额:
    $ 97.27万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了